SANTA BARBARA, Calif. and
INDIANAPOLIS, March 23, 2017 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) and the William Sansum Diabetes Center have
established a research collaboration to improve the lives of Latino
people affected by diabetes through enhanced research, education
and care.
"The tremendous burden of diabetes and cardiovascular disease
bears a disproportionate weight on Latino families in the United States," said David Kerr, M.D., FRCPE, director of Innovation
and Research for the William Sansum Diabetes Center.
"This collaboration with Lilly will allow us to gain a better
understanding of how we can help these families."
Dr. Kerr added that Latino people comprise 43% of the total
population in Santa Barbara
County, and rates of cardio-metabolic disease are
persistently higher than in the rest of the population due to a
combination of factors beyond biological risk, including economics,
culture and education.
For Lilly, the collaboration will provide valuable insights into
patients' unmet needs and aid in the development of
interventions that could improve health outcomes for Latino
people.
"This is a great opportunity for us to further understand the
significant impact of diabetes for Latino families," said
Dara Schuster, M.D., senior director
of U.S. Medical Affairs for Lilly Diabetes. "Through
this collaboration, we will learn where the gaps are so we can
develop meaningful solutions for the unmet needs."
About William Sansum Diabetes Center
The William
Sansum Diabetes Center has been on the cutting edge of diabetes
research, clinical care, and education since its founding in 1944
by Dr. William Sansum, the first
U.S. physician to administer insulin in the treatment of diabetes.
The Center has developed new technologies and produced
groundbreaking diabetes treatments, such as the artificial pancreas
automating delivery of insulin to patients and new protocols for
the management of pregnancies complicated by diabetes. Today, the
Center has international recognition for research and innovation in
the creation, development, and application of novel and effective
smart technologies. The Center is committed to developing effective
approaches to the education of clinicians, people with diabetes and
their families, and healthcare providers in partnership with
academic institutions, specialist diabetes centers, and primary
care colleagues. For more information, please visit
www.sansum.org.
About Lilly Diabetes
Lilly has been a global leader in
diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research and collaboration, a wide range
of therapies and a continued determination to provide real
solutions—from medicines to support programs and more—we strive to
make life better for all those affected by diabetes around the
world. For more information, visit www.lillydiabetes.com or follow
us on Twitter: @LillyDiabetes.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
Refer
to:
|
David Kerr,
MD
|
Julie
Williams
|
|
William Sansum
Diabetes Center
|
Eli Lilly and
Company
|
|
dkerr@sansum.org
|
williamsju@lilly.com
|
|
(805) 682-7640 Ext.
241
|
(317)
627-4056
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-and-the-william-sansum-diabetes-center-announce-a-five-year-research-collaboration-300428388.html
SOURCE Eli Lilly and Company